Grindr to Acquire Freddie, Expanding HIV Prevention Access for Millions
GRND sits 58% above its 52-week low of $9.732.
Summary
Grindr is acquiring PurposeMed, a platform focused on HIV prevention, for $250M, with $190M cash and $60M in stock (3,851,684 shares at $15.58), plus up to $70M earn-out tied to 2027 targets and a 12-month lock-up, to expand access for its user base. The deal aligns with Grindr's health initiatives and could enhance user engagement and retention. The strategic fit is clear given Grindr's LGBTQ+ community focus. This follows a strong Q2 with 33% revenue growth and a recent UK privacy settlement. The acquisition may face regulatory scrutiny but is unlikely to be material to near-term financials.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The purchase agreement provides $190M cash and $60M in stock (3,851,684 shares at $15.58), with a $70M earnout tied to 2027 targets and a 12-month lock-up.
At the time of this announcement, GRND was trading at $15.40 on NYSE in the Technology sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $9.73 to $18.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.